Industry

Vermont Initiative Gives Clinicians New Tools for Infectious Disease Diagnosis and Response

Database and resources will help improve treatment and outcomes BURLINGTON, Vt.–(BUSINESS WIRE)–The Vermont Department of Health has launched a first-of-a-kind program to support healthcare professionals with timely information on disease diagnosis, testing, treatment and patient education resources — improving public health response statewide. The Clinician Support Initiative provides access to a vast collection of images … [Read more…]

Eight Sleep Hires Former Peloton Global Chief Sales Officer, Tim Shannehan, As New Chief Revenue Officer

Tim Shannehan, who spent 8 years at Peloton, joins the sleep fitness company to deliver the next phase of growth for the business MIAMI–(BUSINESS WIRE)–Eight Sleep, the world’s first sleep fitness company has appointed former Chief Sales Officer at Peloton, Tim Shannehan, as Chief Revenue Officer. Shannehan will be reporting to CEO and Co-Founder of … [Read more…]

ObjectiveHealth Expands into New Therapeutic Areas, Adding Dermatology, Urology and Oncology to their Research Portfolio

Expansion will allow partnered specialists to participate in research in their communities NASHVILLE, Tenn.–(BUSINESS WIRE)–ObjectiveHealth, an integrated research provider and embedded technology platform company, announced today they are expanding into additional therapeutic areas which will open new research options to more than 14.4M patients within the communities they serve. Leveraging their proprietary technology solutions, the … [Read more…]

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean reduction of background corticosteroid use. ORRs increased to 94.1% at Week 29 and 88.2% at Week 37 during the safety follow-up period … [Read more…]

ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

– VB119 resulted in profound reductions in B-cells and anti-PLA2R autoantibodies – Three of four evaluable patients had rapid reduction in proteinuria less than one month after initiation of therapy – Complete remission of proteinuria was achieved for the single patient with ≥40 weeks follow up – VB119 was well-tolerated; no study drug related SAEs … [Read more…]

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in … [Read more…]

Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

Updated imetelstat data from IMerge Phase 2 describe significant continuous durable transfusion independence, meaningful reduction in mutational burden and progression-free survival, which indicate disease-modifying activity Ongoing Phase 3 IMerge clinical trial of imetelstat designed to confirm Phase 2 data; top-line results expected in early January 2023 Additional ASH abstracts support the broad potential of imetelstat … [Read more…]

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with relapsed or refractory non-Hodgkin’s lymphoma will be presented … [Read more…]

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter’s syndrome New data evaluating investigational … [Read more…]

Electromed, Inc. to Participate in Two Upcoming Investor Conferences

NEW PRAGUE, Minn.–(BUSINESS WIRE)–Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that management is scheduled to participate in two upcoming investor conference during the month of November 2022: Sidoti & Company November Micro-Cap Virtual Conference on November 9-10, 2022. Three Part Advisors 14th Annual Southwest … [Read more…]